Skip to main content
Equibles

RGNT · Regentis Biomaterials Ltd.

Track RGNT — free

Use RGNT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGNT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.49 +0.02 (+1.36%) At close · Oct 21
Rebalance outlook locked
Market Cap
$10.47M
Shares
7.02M
Volume · Oct 21 14.16K Avg daily vol (3M) 56.33K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.49 Open$1.51 Day$1.48–1.56 Available close range$1.28–9.40 Avg vol 30d55K Short int4K · 0.1% float · 1.0d Short vol43% DataDec 2025–Oct 2026

The closing range uses available history since Dec 4, 2025; less than a full year is stored.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$13.02M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-79.5%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.52
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −53%
below
Price vs 50-day avg −21%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −29%
trailing
6-month return −49%
trailing
YTD return −78%
this year
Relative strength −56%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.05% of float · ▼ -42.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Squeeze score 28
low risk · 0–100
Fundamentals
Fair
EPS growth −1505%
Y/Y
Balance sheet $6.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 590%
annualized · 1-yr
Max drawdown −84%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−53% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.05% of float · ▼ -42.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Price context
position in its available closing range
Range low $1 Now $1 · 3% Range high $9
vs 200-day avg -53% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RGNT
Regentis Biomaterials Ltd.
this stock
$10.47M -77.9% — — 0.1%
ISRG
Intuitive Surgical Inc
 $151.25B -24.4% +20.5% 52.9 2.1%
BDX
Becton Dickinson & Co
 $52.93B — +8.2% — 3.6%
MDLN
Medline Inc.
 $46.42B -15.9% +11.5% — 4.0%
RMD
Resmed Inc
 $35.51B +2.2% +13.4% 23.6 8.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
6
% held
12.0%
Net QoQ
+293.9K sh
Top holder
Rosalind Advisors, Inc.
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
3.8K
Days to cover
1.0d
Change
-2.8K sh
View
Short Volume
Short vol %
43%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$1.9K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
50.3%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-13.6M
EPS diluted
$-24.16
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 13, 2026
This year
23

Regentis Biomaterials Ltd. reported strong surgeon interest in GelrinC® at the 8th ICRS Summit in Porto, Portugal, while expanding European Centers of Excellence for training and commercialization; its U.S. FDA pivotal study has completed over 50% enrollment.

View
Exempt Offerings
Offering
$6.5M
Filed
Jun 25, 2026
View

Performance

5D 20D 120D MTD YTD
RGNT -1.3% -29.1% -48.8% -17.7% -77.9%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY -1.8% -29.7% -56.4% -19.1% -91.3%
Key facts CIK 1912966 CUSIP M8211G108 Visit website Investor relations